Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 9/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456628 | 0.87 | PBRM1 (0.40) | PBRM1CYP19A1CA1CA2CA4 | |
| SCHEMBL29640600 | 0.87 | PBRM1 (0.40) | PBRM1CYP19A1CA1CA2CA4 | |
| SCHEMBL27953581 | 0.83 | MAPT (0.50) | CA1CA2CA7CA9MALT1 | |
| SCHEMBL1981866 | 0.80 | APP (0.42) | PBRM1APPCYP19A1CA1CA2 | |
| SCHEMBL3183702 | 0.80 | FABP6 (0.46) | CYP19A1CA1CA2CA7CA9 | |
| SCHEMBL15539153 | 0.79 | APP (0.41) | PBRM1APPCYP19A1CA1CA2 | |
| SCHEMBL7034343 | 0.78 | PBRM1 (0.48) | PBRM1APPCYP19A1AR | |
| SCHEMBL15550456 | 0.78 | APP (0.40) | PBRM1APPCYP19A1CA1CA2 | |
| SCHEMBL15537318 | 0.76 | APP (0.40) | PBRM1APPCYP19A1CA1CA2 | |
| SCHEMBL29448029 | 0.75 | PKM (0.47) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650336-B2 | Mono-fluoro beta-secretase inhibitors | ASTRAZENECA AB (SE) | 2017-05-16 | — | — | US | disclosed |
| EP-2780321-B1 | MONO-FLUORO BETA-SECRETASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-12-30 | — | — | EP | disclosed |
| US-20140288091-A1 | MONO-FLUORO BETA-SECRETASE INHIBITORS | ASTRAZENECA AB (SE) | 2014-09-25 | — | — | US | disclosed |
| EP-2780321-A1 | MONO-FLUORO BETA-SECRETASE INHIBITORS | Astrazeneca AB (SE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013054108-A1 | MONO-FLUORO BETA-SECRETASE INHIBITORS | ASTRAZENECA AB (SE) | 2013-04-18 | — | — | WO | disclosed |
| WO-2011072064-A1 | S PIRO [CHROMAN - 4, 4 ' - IMIDAZOL] ONES AS BETA - SECRETASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288091-A1 | MONO-FLUORO BETA-SECRETASE INHIBITORS | BACE1, BACE2, PSEN1 | PBRM1 1404/4885APP 4/4885CYP19A1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.